Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration

  • Authors:
    • Yanting Duan
    • Bo Hu
    • Chunxia Qiao
    • Longlong Luo
    • Xinying Li
    • Jing Wang
    • Hao Liu
    • Tingting Zhou
    • Beifen Shen
    • Ming Lv
    • Jiannan Feng
  • View Affiliations

  • Published online on: April 15, 2019     https://doi.org/10.3892/ol.2019.10255
  • Pages: 5784-5792
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

AXL receptor tyrosine kinase ligand (AXL), a tyrosine kinase receptor that is commonly overexpressed in numerous types of cancer, significantly promotes drug resistance and metastasis in tumor cells. Inhibition of the AXL/growth arrest‑specific 6 (Gas6) signaling pathway is emerging as a potential anticancer therapeutic strategy. In the present study, on the basis of the three‑dimensional complex structure of AXL/Gas6, the critical residues (E56, E59 and T77) in AXL binding to Gas6 were determined using computer graphics analysis and the distance geometry method. Subsequently, four‑variant AXL‑ECD‑Fc‑M1 (G32S, D87G, V92A and G127R) and AXL‑ECD‑Fc‑M2 (G32A, D87A, V92A and G127A) were predicted as high‑affinity mutants; AXL‑ECD‑Fc‑M3 (E56R and T77R) and AXL‑ECD‑Fc‑M4 (E59R and T77R) were predicted as low‑affinity mutants. The results of the present study revealed that the half‑maximal effect concentrations of AXL‑ECD‑Fc‑M1 and AXL‑ECD‑Fc‑M2 were ~0.141 and 0.375 µg/ml, respectively, whereas that of the wild‑type protein (AXL‑ECD‑Fc‑WT) was 0.514 µg/ml. Furthermore, adding the high‑affinity mutants into culture medium to capture free Gas6 significantly inhibited AXL/Gas6 binding and thus blocked the downstream signaling pathway. In addition, the high‑affinity mutants effectively suppressed the migration and metastasis of SKOV3 and A549 cells. Conversely, compared with AXL‑ECD‑Fc‑WT, the low‑affinity AXL mutants AXL‑ECD‑Fc‑M3 and AXL‑ECD‑Fc‑M4 lost all inhibitory activities. These findings highlight AXL as a potential therapeutic target and demonstrated that the key residues E56, E59 and T77 may be crucial sites for abolishing the activity of the AXL/Gas6 pathway in cancer therapy.

References

1 

Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Myers SH, Brunton VG and Unciti-Broceta A: AXL inhibitors in cancer: A medicinal chemistry perspective. J Med Chem. 59:3593–3608. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Graham DK, DeRyckere D, Davies KD and Earp HS: The TAM family: Phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 14:769–785. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, et al: R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70:1544–1554. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Paccez JD, Vogelsang M, Parker MI and Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Int J Cancer. 134:1024–1033. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Sheridan C: First Axl inhibitor enters clinical trials. Nat Biotechnol. 31:775–776. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, et al: Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 107:1124–1129. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H and Maitra A: The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther. 8:618–626. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY and Lin WC: Clinical significance of AXL kinase family in gastric cancer. Anticancer Res. 22:1071–1080. 2012.

10 

Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol. 204:36–44. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, et al: A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 4:816–827. 2014. View Article : Google Scholar : PubMed/NCBI

12 

Hong J, Peng D, Chen Z, Sehdev V and Belkhiri A: ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res. 73:331–340. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM and Chuang SE: Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268:314–324. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, et al: Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 5:57122014. View Article : Google Scholar : PubMed/NCBI

16 

Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, et al: Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 35:2687–2697. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, et al: Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance. Cancer Discov. 6:382–399. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Nagata K, Nakano T, Arita H, Zong C, Hanafusa H and Mizuno K: Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem. 271:30022–30027. 1996. View Article : Google Scholar : PubMed/NCBI

19 

Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, et al: Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature. 373:623–626. 1995. View Article : Google Scholar : PubMed/NCBI

20 

Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Göhring W, Ullrich A, Timpl R and Hohenester E: Structural basis for Gas6-Axl signalling. EMBO J. 25:80–87. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW, Manro JR, et al: LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 31:833–844. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, et al: Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene. 33:5405–5414. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Cerchia L, Esposito CL, Camorani S, Rienzo A, Stasio L, Insabato L, Affuso A and de Franciscis V: Targeting Axl with a high-affinity inhibitory aptamer. Mol Ther. 20:2291–2303. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, et al: The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 507:508–512. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-Axl monoclonal antibody attenuates xenogra tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Kariolis MS, Miao YR, Jones DS II, Kapur S, Mathews II, Giaccia AJ and Cochran JR: An engineered Axl ‘decoy receptor’ effectively silences the Gas6-Axl signaling axis. Nat Chem Biol. 10:977–983. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, et al: Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 24:203–212. 2018. View Article : Google Scholar : PubMed/NCBI

28 

Chen PX, Li QY and Yang Z: Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann Diagn Pathol. 17:425–429. 2013. View Article : Google Scholar : PubMed/NCBI

29 

Darling RJ and Brault PA: Kinetic exclusion assay technology: Characterization of molecular interactions. Assay Drug Dev Technol. 2:647–657. 2004. View Article : Google Scholar : PubMed/NCBI

30 

Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J and Lemke G: Differential TAM receptor ligand phospholipid interactions delimit differential TAM bioactivities. Elife; 3. 2014

31 

Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A, Lindgren D, et al: Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci USA. 111:13373–13378. 2014. View Article : Google Scholar : PubMed/NCBI

32 

Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Duan, Y., Hu, B., Qiao, C., Luo, L., Li, X., Wang, J. ... Feng, J. (2019). Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration. Oncology Letters, 17, 5784-5792. https://doi.org/10.3892/ol.2019.10255
MLA
Duan, Y., Hu, B., Qiao, C., Luo, L., Li, X., Wang, J., Liu, H., Zhou, T., Shen, B., Lv, M., Feng, J."Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration". Oncology Letters 17.6 (2019): 5784-5792.
Chicago
Duan, Y., Hu, B., Qiao, C., Luo, L., Li, X., Wang, J., Liu, H., Zhou, T., Shen, B., Lv, M., Feng, J."Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration". Oncology Letters 17, no. 6 (2019): 5784-5792. https://doi.org/10.3892/ol.2019.10255